Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Libtayo cemiplimab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Retevmo selpercatinib Thyroid cancer Reimburse with clinical criteria and/or conditions Complete
Qinlock ripretinib Gastrointestinal stromal tumours Reimburse with clinical criteria and/or conditions Complete
Retevmo selpercatinib Thyroid cancer Reimburse with clinical criteria and/or conditions Complete
Xpovio selinexor Multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Scemblix asciminib Philadelphia chromosome-positive chronic myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Saphnelo anifrolumab Systemic lupus erythematosus Reimburse with clinical criteria and/or conditions Complete
Tecentriq atezolizumab Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Poteligeo mogamulizumab mycosis fungoides (MF), Sézary syndrome (SS) Reimburse with clinical criteria and/or conditions Complete
Jakavi ruxolitinib Graft versus host disease Reimburse with clinical criteria and/or conditions Complete